Proxima Assembles Scientific Supergroup to Unlock 'Undruggable' Diseases

NEW YORK, NY – March 05, 2026 – In a strategic move that has sent ripples through the biotech industry, Proxima, a frontier AI and data generation company, has appointed a trio of scientific luminaries to its Scientific Advisory Board (SAB). The appointments of Dr. Raymond Deshaies, Dr. Lyn Jones, and Dr. Juri Rappsilber—titans in the fields of protein degradation, chemical biology, and structural proteomics—signal a powerful consolidation of expertise aimed at conquering one of modern medicine's greatest challenges: the vast landscape of previously 'undruggable' diseases.

This 'supergroup' of advisors brings together the foundational pillars of proximity therapeutics, a revolutionary class of medicines that don't just inhibit disease-causing proteins but co-opt the cell's own machinery to eliminate or modify them. The move significantly bolsters the credibility of Proxima's platform, which combines artificial intelligence with high-throughput data generation to design these next-generation drugs. For investors and industry observers, the message is clear: Proxima is positioning itself not just as a participant, but as a leader in a field poised to redefine therapeutic intervention.

A Brain Trust to Redefine Drug Discovery

The strategic value of these appointments cannot be overstated. Each new advisor brings a unique and critical piece of the puzzle.

Dr. Raymond Deshaies, a member of the National Academy of Sciences and former SVP of Global Research at Amgen, is a foundational figure in the field. He co-conceived the PROTAC (proteolysis-targeting chimera) concept, a technology that uses small molecules to tag unwanted proteins for destruction by the cell's internal disposal system. His involvement lends immense validation to Proxima's core mission.

“Some of the most powerful drugs ever discovered, such as lenalidomide and thalidomide, turned out to work by hijacking the cell's own protein disposal machinery,” Dr. Deshaies explained in the company's announcement. “The principle of induced proximity is using small molecules to leverage tools from nature's playbook, and we've barely scratched the surface of what's therapeutically possible with it.”

Joining him is Dr. Lyn Jones, a Principal Investigator at the prestigious Dana-Farber Cancer Institute and an expert in molecular glues—smaller, more nuanced molecules that induce proximity between proteins. His work is crucial for expanding the toolkit of proximity therapeutics beyond the few well-trodden paths.

“The human genome encodes more than 600 E3 ubiquitin ligases, and thousands of other proteins with potential in proximity applications, but we’ve built almost everything so far on just two of them,” noted Dr. Jones. “If we want to expand the druggable proteome, we need to understand the protein interfaces of new effector proteins in detail. To get there, you need structural data on these interfaces at a scale that hasn't yet existed.”

Rounding out the trio is Dr. Juri Rappsilber, Chair of Bioanalytics at Technische Universität Berlin. Dr. Rappsilber is the pioneer behind cross-linking mass spectrometry (XL-MS), a technology capable of mapping the intricate web of protein interactions inside a living cell. This is the very data Dr. Jones highlights as essential, and it forms the bedrock of Proxima's entire platform.

Beyond the Hype: Technology to Map the Interactome

Proxima's core thesis is that the primary bottleneck in designing new proximity drugs is a lack of data. While the concept is powerful, rationally designing molecules that can precisely connect two specific proteins within the crowded environment of a cell is extraordinarily difficult. It is estimated that the structures for over 95% of the human protein-protein interactions remain unmapped.

This is where Proxima, formerly known as VantAI, aims to differentiate itself from a crowded field of competitors like Arvinas, Kymera Therapeutics, and Nurix. While many firms focus on optimizing known chemistries, Proxima is tackling the more fundamental problem of data generation. The company's platform is designed to industrialize Dr. Rappsilber’s XL-MS techniques, generating unprecedented volumes of structural data on how proteins interact at a proteome-wide scale.

“The limiting factor in cross-linking mass spectrometry has historically been throughput,” said Dr. Rappsilber. “Proxima’s platform represents an important step in this direction. By industrializing cross-linking mass spectrometry... and pairing it directly with computational structure prediction, Proxima is demonstrating what becomes possible when this data is generated at a depth and scale the field has long envisioned.”

This massive dataset is then fed into Proxima's proprietary 'frontier AI' models. These models analyze the complex structural information to predict how small molecules can be designed to act as 'matchmakers' or 'adapters', effectively rewiring the cell's circuitry to fight disease. This self-reinforcing flywheel—generating novel data to train better AI, which in turn helps direct more effective data generation—is what the company believes will unlock the full potential of proximity therapeutics.

A Multi-Billion Dollar Market in the Making

Proxima's ambitious strategy is unfolding within one of the hottest sectors in biopharma. The market for targeted protein degradation and other proximity therapeutics is experiencing explosive growth, with some analyst projections reaching over $12 billion by the early 2030s. This boom is fueled by the potential to finally drug the 85% of the proteome that has remained inaccessible to traditional small molecule inhibitors.

This potential has not gone unnoticed by big pharma or venture capital. Proxima itself is backed by an oversubscribed $80 million seed round led by DCVC, with notable participation from NVentures, NVIDIA's venture arm, and Roivant. More importantly, the company has already forged multi-billion-dollar alliances with industry giants including Johnson & Johnson (via its acquisition of Halda Therapeutics) and Bristol Myers Squibb. These partnerships serve as powerful external validation of Proxima's technology and have already produced co-developed programs reportedly advancing toward clinical trials in 2026.

While Proxima builds its foundational platform, the broader field is already seeing clinical success. Drugs like Golcadomide are in Phase III trials for B-cell Lymphoma, proving the viability of the approach. This clinical progress de-risks the entire class of medicines and paves a regulatory pathway that Proxima and its partners can follow.

By assembling a scientific advisory board of this caliber, Proxima is not just acquiring guidance; it is making a definitive statement about its ambition. The company is betting that the combination of its pioneering advisors' insights, its unique data generation engine, and its powerful AI can solve the fundamental challenges of the field. If successful, this approach could systematically illuminate the 'dark matter' of the human proteome, turning previously untreatable diseases into manageable conditions and truly rewriting the rules of medicine.